World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
68
Citations
26293
World Ranking
2124
National Ranking
890

Roy M. Gulick publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Roy M. Gulick sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 228 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Roy M. Gulick D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Roy M. Gulick sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 68 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Roy M. Gulick is a researcher affiliated with Cornell University in the United States with a focus on medicine, particularly within infectious diseases. Their work spans multiple subfields, including infectious diseases, virology, epidemiology, neurology, and emergency medicine.

The main topics of Roy M. Gulick's research encompass:

  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • HIV-related health complications and treatments
  • COVID-19 and healthcare impacts

Roy M. Gulick has contributed to numerous publications, with frequent appearances in the following venues:

  • UNC Libraries
  • Annals of Internal Medicine
  • Clinical Infectious Diseases
  • New England Journal of Medicine
  • AIDS and Behavior

Recent representative papers include:

  • "Clinical Characteristics of Covid-19 in New York City" (2020), New England Journal of Medicine
  • "Severe Covid-19" (2020), New England Journal of Medicine
  • "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women" (2021), New England Journal of Medicine
  • "COVID-19 in Hospitalized Adults With HIV" (2020), Open Forum Infectious Diseases
  • "Obesity and COVID-19 in New York City: A Retrospective Cohort Study" (2020), Annals of Internal Medicine

Collaborations form an important part of Roy M. Gulick's work, with frequent coauthors including:

  • Raphael J. Landovitz
  • Kenneth H. Mayer
  • Eric S. Daar
  • Marybeth McCauley
  • Mark A. Marzinke

Recognized by peers, Roy M. Gulick is a member of the Association of American Physicians, reflecting a standing within the medical community.

Best Publications

  • Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    R M Gulick;J W Mellors;D Havlir;J J Eron

  • Clinical Characteristics of Covid-19 in New York City.

    Parag Goyal;Justin J. Choi;Laura C. Pinheiro;Edward J. Schenck

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Severe Covid-19

    David A. Berlin;Roy M. Gulick;Fernando J. Martinez

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Marina Caskey;Florian Klein;Julio C. C. Lorenzi;Michael S. Seaman

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

    David W Haas;Heather J Ribaudo;Richard B Kim;Camlin Tierney

  • Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

    Roy M. Gulick;Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Stephanie Lustgarten

  • Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

    Patrice Severe;Marc Antoine Jean Juste;Alex Ambroise;Ludger Eliacin

  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression

    Pilar Mendoza;Henning Gruell;Lilian Nogueira;Joy A. Pai

  • HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

    Johannes F. Scheid;Johannes F. Scheid;Joshua A. Horwitz;Yotam Bar-On;Edward F. Kreider

  • Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Marina Caskey;Till Schoofs;Henning Gruell;Allison Settler

  • Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti

    Patrice Severe;Paul Leger;Macarthur Charles;Francine Noel

  • Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

    David B. Clifford;Scott Evans;Yijun Yang;Edward P. Acosta

  • Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

    Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  • ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

    Robert L. Murphy;Scott Brun;Charles Hicks;Joseph J. Eron

  • Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection: 100-Week Follow-up

    Roy M. Gulick;John W. Mellors;Diane Havlir;Joseph J. Eron

  • Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

    Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Christina Lalama

  • 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

    Roy M. Gulick;John W. Mellors;Diane Havlir;Joseph J. Eron

Frequent Co-Authors

Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Edward P. Acosta
Edward P. Acosta University of Alabama at Birmingham
David W. Haas
David W. Haas Vanderbilt University Medical Center
Richard Haubrich
Richard Haubrich University of California, San Diego
Charles Flexner
Charles Flexner Johns Hopkins University
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Robert L. Murphy
Robert L. Murphy Northwestern University
Susan A. Fiscus
Susan A. Fiscus University of North Carolina at Chapel Hill
Eric S. Daar
Eric S. Daar Lundquist Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to Microbiology can open diverse career paths, especially for students seeking flexible learning options. For those interested in public health, considering mph online programs with easy admission requirements is a smart way to advance without the stress of strict entry criteria.

Many graduates also explore allied health fields. For example, becoming a child.life specialist salary can be rewarding, combining science knowledge with emotional support skills.

Importantly, online education provides accessible opportunities for diverse populations, including those with past convictions. Programs highlighted under college degrees for felons demonstrate how higher education can be inclusive and supportive, allowing individuals to rebuild their careers.

For those interested in nursing and holistic health, functional medicine np programs offer specialized tracks that blend traditional microbiology with innovative patient care approaches.

Altogether, these pathways illustrate the versatility of microbiology foundations and the wide range of accessible online degrees that can lead to meaningful, well-paying careers.

Best Scientists Citing Roy M. Gulick

Trending Scientists

Recently Published Articles